Cargando…

MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC

Triple-negative breast cancers (TNBCs) are heterogeneous and aggressive, with high mortality rates. TNBCs frequently respond to chemotherapy, yet many patients develop chemoresistance. The molecular basis and roles for tumor cell–stromal crosstalk in establishing chemoresistance are complex and larg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franklin, Derek A., Sharick, Joe T., Ericsson-Gonzalez, Paula I., Sanchez, Violeta, Dean, Phillip T., Opalenik, Susan R., Cairo, Stefano, Judde, Jean-Gabriel, Lewis, Michael T., Chang, Jenny C., Sanders, Melinda E., Cook, Rebecca S., Skala, Melissa C., Bordeaux, Jennifer, Orozco Bender, Jehovana, Vaupel, Christine, Geiss, Gary, Hinerfeld, Douglas, Balko, Justin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455066/ https://www.ncbi.nlm.nih.gov/pubmed/32634121 http://dx.doi.org/10.1172/jci.insight.134290

Ejemplares similares

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
por: Luo, Na, et al.
Publicado: (2018)

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer
por: Hanna, Ann, et al.
Publicado: (2022)

MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
por: Franklin, Derek A., et al.
Publicado: (2020)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

SOX4-SMARCA4 complex promotes glycolysis-dependent TNBC cell growth through transcriptional regulation of Hexokinase 2
por: Khanna, Pooja, et al.
Publicado: (2023)

Cellular Metabolic Heterogeneity In Vivo Is Recapitulated in Tumor Organoids()
por: Sharick, Joe T., et al.
Publicado: (2019)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

Fluorescence lifetime imaging microscopy: fundamentals and advances in instrumentation, analysis, and applications
por: Datta, Rupsa, et al.
Publicado: (2020)

Integrated analysis reveals the participation of IL4I1, ITGB7, and FUT7 in reshaping the TNBC immune microenvironment by targeting glycolysis
por: Xu, Tao, et al.
Publicado: (2021)

The Evaluation of Cytotoxic Properties from CCB-2 Sugar Complexes Against TNBC and Non-TNBC Cells
por: Jenie, Riris Istighfari, et al.
Publicado: (2021)

TNBC invasion: downstream of STAT3
por: Jackson, James G., et al.
Publicado: (2017)

Redox imaging and optical coherence tomography of the respiratory ciliated epithelium
por: Gil, Daniel A., et al.
Publicado: (2019)

The Potential of PSMA as a Vascular Target in TNBC
por: Heesch, Amelie, et al.
Publicado: (2023)

Aptamer-Based Strategies to Boost Immunotherapy in TNBC
por: Agnello, Lisa, et al.
Publicado: (2023)

Endorsement of TNBC Biomarkers in Precision Therapy by Nanotechnology
por: Chaudhuri, Aiswarya, et al.
Publicado: (2023)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Drug response in organoids generated from frozen primary tumor tissues
por: Walsh, Alex J., et al.
Publicado: (2016)

Author Correction: Drug response in organoids generated from frozen primary tumor tissues
por: Walsh, Alex J., et al.
Publicado: (2019)

Protein-bound NAD(P)H Lifetime is Sensitive to Multiple Fates of Glucose Carbon
por: Sharick, Joe T., et al.
Publicado: (2018)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

LC–MS Based Lipidomics Depict Phosphatidylethanolamine as Biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 Cells
por: Estrada-Pérez, Alan Rubén, et al.
Publicado: (2022)

Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer
por: Nokin, Marie-Julie, et al.
Publicado: (2019)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Leveraging MYC as a therapeutic treatment option for TNBC
por: Carey, Jason P.W., et al.
Publicado: (2018)

Optimization of Short RNA Aptamers for TNBC Cell Targeting
por: Camorani, Simona, et al.
Publicado: (2022)

Heme Oxygenase Modulation Drives Ferroptosis in TNBC Cells
por: Consoli, Valeria, et al.
Publicado: (2022)

TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors
por: Carroll, Natalie, et al.
Publicado: (2022)

An Magnetic-Targeting Nano-Diagnosis and Treatment Platform for TNBC
por: Zhang, Mengqi, et al.
Publicado: (2023)

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer
por: Gonzalez-Ericsson, Paula I., et al.
Publicado: (2021)

Caudatin blocks the proliferation, stemness and glycolysis of non-small cell lung cancer cells through the Raf/MEK/ERK pathway
por: Hou, Juan, et al.
Publicado: (2022)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

MEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
por: Evans, Catherine, et al.
Publicado: (2013)

Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance
por: James, Jamaal L, et al.
Publicado: (2023)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities
por: Camorani, Simona, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rslqi98bri2reftkbuodq6tjfv